Brian I. Rini MD, FACPProfessor of Medicine, Lerner College of Medicine, Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland, Ohio
Brian I. Rini, MD, FACP is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology and Co-Leader of the Genitourinary Program of the CASE Comprehensive Cancer Center, Dr. Rini’s work focuses on genitourinary malignancies.
Dr. Rini earned his medical degree at the Ohio State University College of Medicine. Dr. Rini completed a Residency program in Internal Medicine and a Fellowship in Hematology / Oncology at University of Chicago Hospitals. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to The Cleveland Clinic.
Dr. Rini’s primary research has been in renal cell carcinoma (RCC) and prostate cancer, with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini has been involved in the initial and ongoing development of targeted agents for metastatic RCC, and was an integral investigator in the clinical development of several agents which are now FDA approved. Dr. Rini was the Principal Investigator of an international phase III cooperative group trial of bevacizumab plus interferon and the PI of the phase III axitinib trial in metastatic RCC that lead to FDA approval, and is currently the PI of several global phase III trials in RCC.
Dr. Rini’s research has been published in peer-reviewed journals that include Journal of the National Cancer Institute, Journal of Clinical Oncology, Cancer, Lancet and JAMA. He is a member of the editorial boards of Journal of Clinical Oncology and Co-Chair of the NCI RCC Task Force.
Recent Contributions to PracticeUpdate:
- Renal Cell Carcinoma: Biomarkers and Side Effects Associated With RCC Treatments—Part 5
- Renal Cell Carcinoma: Second-Line Therapy for RCC—Part 4
- Renal Cell Carcinoma: Non-Clear Cell RCC—Part 3
- Renal Cell Carcinoma: Frontline Treatment—Part 2
- Adjuvant Treatment of RCC—Part 1
- Ipi/Nivo is the New Standard of Care in mRCC
- Kidney Cancer Symposium: Part 1—Frontline Therapy for RCC
- Kidney Cancer Symposium: Part 2—Implications of TKI-Related Toxicity